# RISK AWARENESS FORM FOR COUNSELLING THE PATIENT TO ENSURE THE PATIENT IS FULLY INFORMED ABOUT THE SAFE USE OF POMALIDOMIDE

This Risk Awareness Form is to assist you with counselling a patient before they commence pomalidomide treatment in order to ensure it is used safely and correctly. It must be completed for each male prior to the initiation of their pomalidomide treatment.

The purpose of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse drug reactions associated with the use of pomalidomide. It is mandatory that male patients receive counselling and education to be made aware of the risks of pomalidomide.

The form should be retained with their medical records, and a photocopy provided to the patient. It is not a contract and does not absolve anybody from his/her responsibilities regarding the safe use of the product and prevention of foetal exposure.

Warning: Pomalidomide must not be taken during pregnancy, since a teratogenic effect in humans is expected. Pomalidomide is structurally related to thalidomide. Thalidomide is a known human teratogen that causes severe life-threatening birth defects. Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis. The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.

If pomalidomide is taken during pregnancy it is expected to cause severe birth defects or death to an unborn baby.

#### **Patient Details**

Patient First Name																					
Patient Last Name																					
Date of Birth	D	D	N	ΛМ	ΥY	ΥΥ	Counselling Date		D	D	N	M		Υ	ΥY	Υ					

#### Did you inform your patient:

		Male
1.	Of the need to avoid foetal exposure	Tick
2.	To not share the medicinal product with any other person.	Tick
3.	That they should not donate blood during treatment (including during dose interruptions) and for at least 7 days following discontinuation of pomalidomide.	Tick
4.	That they should return the unused capsules to the pharmacist at the end of treatment	Tick
5.	Of the effective contraceptive measures he or his female partner can use.	Tick
6.	That pomalidomide is found in semen, so there is a need to use condoms if the sexual partner is pregnant or is a woman of childbearing potential not on effective contraception (even if the man has had a vasectomy) throughout treatment duration, during dose interruption and for at least 7 days after cessation of treatment.	Tick
7.	That if his partner becomes pregnant, he should inform his treating prescriber	Tick

	immediately, his partner should be referred to a physician specialised or experienced in teratology for evaluation and advice.	
8.	That he should not donate semen during treatment (including during dose interruptions) and for at least 7 days following discontinuation of pomalidomide.	Tick
9.	Of hazards and necessary precautions associated with use of pomalidomide.	Tick
10	. Of the thromboembolic risk and possible requirement to take thromboprophylaxis during treatment with pomalidomide.	Tick

### Can you confirm your patient:

Is capable of complying with contraceptive measures?	YES	NO
--	-----	----

#### **Pregnancy Prevention**

The Patient Confirms that:								
They will use a condom during intercourse with a woman of childbearing potential	Tick							
Their female partner is using an effective method of contraception	Tick							
Their female partner is of non-childbearing potential	Tick							
They are committed to complete and absolute abstinence	Tick							

#### **Prescriber Confirmation**

I have fully explained to the patient named above the nature, purpose and risks of the treatment associated with pomalidomide, especially the risks to women of childbearing potential. I will comply with all my obligations and responsibilities as the prescriber of pomalidomide.

Prescriber First Name																				
Prescriber Last Name																				
Prescriber Signature								Da	ate	ı		DI	D	N	IM		Y	ΥΥ	Y	

# Patient: please read thoroughly and initial the adjacent box if you agree with the statement

I understand that severe birth defects may occur with the use of pomalidomide. I have been warned by my prescriber that any unborn baby has a high risk of birth defects and could even die if a woman is pregnant or becomes pregnant while taking pomalidomide.	Patient Initials
I have been told by my prescriber that I must NEVER have unprotected sexual contact with women who are pregnant or may become pregnant, whilst I am taking pomalidomide and for at least 7 days after stopping treatment.	Patient Initials
I understand that pomalidomide passes into human semen. If my partner is pregnant or able to become pregnant, and she doesn't use effective contraception, I must use condoms throughout the duration of my treatment, during dose interruptions and for at least 7 days after I stop pomalidomide even if I have had a vasectomy.	Patient Initials
I understand that if my partner does become pregnant whilst I am taking pomalidomide or within 7 days after I have stopped taking pomalidomide I should inform my prescriber immediately and my partner should be referred to a physician specialised or experienced in teratology for evaluation and advice.	Patient Initials
I understand that pomalidomide will be prescribed ONLY for me. I must not share it with ANYONE	Patient Initials
I have read and understand the Pomalidomide Patient Guide and understand the contents, including the information about other possible important health problems (side effects) associated with the use of pomalidomide.	Patient Initials
I know that I cannot donate blood while taking pomalidomide (including dose interruptions) and for at least 7 days after stopping treatment.	Patient Initials
I know that I cannot donate semen or sperm while taking pomalidomide, during dose interruptions and for at least 7 days after discontinuation of pomalidomide.	Patient Initials
I understand that I must return any unused pomalidomide capsules to my pharmacy at the end of my treatment	Patient Initials
I have been informed about the effective contraceptive methods that my female partner can use.	Patient Initials
I have been informed about the thromboembolic risk and possible requirement to take thromboprophylaxis during treatment with pomalidomide.	Patient Initials
I understand that my prescriber will send or may provide me with a completed 'Prescription Authorisation Form' with each pomalidomide prescription for the pharmacy.	Patient Initials
I understand that the 'Prescription Authorisation Form' contains non-identifiable information about me, which will ensure pomalidomide is dispensed safely. This information may be used by the Marketing Authorisation Holder and the distributor for the product I receive and the Health Products Regulatory Authority (HPRA) to evaluate the safe use of pomalidomide.	Patient Initials

#### **Patient Confirmation**

I confirm that I understand and will comply with the requirements of the POMALIDOMIDE Pregnancy Prevention Programme, and I agree that my prescriber can initiate my treatment with pomalidomide.

Your personal data is used solely for the purpose of entering you into the Pomalidomide Pregnancy Prevention Programme and is processed by the marketing authorisation holder (MAH) of the pomalidomide product you receive, its third party service providers and any worldwide Affiliates the MAH may have, for the purposes of compliance with the Risk Management Plan legal obligations and for storage purposes. Third party service providers include, for example, the distributor of the pomalidomide product you receive.

Your pharmacist can confirm the details of the MAH for the pomalidomide product you are given and this will also be mentioned on the packaging and package leaflet. Queries on how your personal data will be processed can be directed to the MAH in question, by consulting their publicly available information (e.g. on their website) which details how they process your personal data and provides a contact point for any queries in relation to their use of your personal data.

Patient Signature	Date	DD	MM	YYYY
----------------------	------	----	----	------

#### Statement of the interpreter (Where Appropriate)

I have interpreted the information above to the patient/parent/carer to the best of my ability and in a way in which I believe she/he/they can understand. She/he/they agree to follow the necessary precautions to prevent an unborn child being exposed to pomalidomide.

Signed:	Name: (Print)		Date	DD	MM	YYYY	
---------	------------------	--	------	----	----	------	--

## Important Safety Information:

This is risk minimisation material and is provided as a collaborative project between Accord Healthcare Ireland Ltd. AS Grindeks and Teva Pharmaceuticals Ireland. For further information, please refer to the Summary of Product Characteristics (SmPC) for the respective medicinal product from the relevant Marketing Authorisation Holder available at www.hpra.ie

Version 3.0

Approved by HPRA: 21-AUG-2025